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Results: Male female ratio was 4:1 and age group (24-58y). The
mean ESDwas 63 (56-78) Mean EDDwas 50 (46-54). However at the
mean ESD of 50 mm the EDD was quiet variable between (58-
72mm).We observed EDD to scatter much from themean and ESD
showed less variation. The LVEFwas linearly correlating with both
EDD and ESD. Severe LV dysfunction (< 25 %) was more related to
larger ESDs. When mitral regurgitation was present ESD were
better correlated with LV dysfunction. The impact of intensive
medical management on LV dimension was also studied in 5 pa-
tients. The regression of EDD was more rapid than ESD .An
empirical reduction > 5mm in ESD was considered significant. It
was achieved only in two, while EDD regression was documented
in all. Functional class improvement and 6 minute walk test
showed a positive trend only in patients whose ESD regressed.
Conclusions: We conclude LVESD is amore scientific parameter to
diagnose DCM than LVEDD. It is also a better index to assess and
follow-up these patients. In our series, a mean LVESD of more
than 50 mm predicted all significant DCMs .We suggest there is a
need for a larger study on this issue. We may universalize the
definition of DCM based on LVESD rather than LVEDD.
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Background: Ranolazine is a unique anti anginal drug with un-
defined mechanisms of action. In the present study we were
aimed to identify the role of ranolazine in improving left ven-
tricular function by various echocardiographic parameters and to
identify its effect on a unique oxidative stress marker Malo-
naldehyde in patients with post myocardial infarction left ven-
tricular dysfunction who underwent revascularization by
percutaneous interventions.
Methods: Prospectively one hundred (100) cases and forty (40)
controls with LV dysfunction were recruited in this study with 6
months of follow up and all baseline and demographic parame-
ters, clinical features and symptomatology with blood chemistry
parameters were collected for all patients. All patients underwent
detailed echocardiography at baseline and at 6 months and serum
Malonaldehyde levels were also analyzed at baseline and 6
months. The echocardiographic parameters studied were ejection
fraction [{LV volume in end diastole (LVEDV) - LV volume in end
systole (LVESV)}/ LVEDV}, fractional shortening ((LVEDd-LVESd) /
LVEDd expressed as a percentage e d is dimension) and peak
mitral annular velocity (degree of movement of mitral annulus
during systole e PMAV) by Doppler. Malondialdehyde (MDA) is
one of the most frequently used indicators of lipid peroxidation.
We used plasma MDA levels to know the degree of oxidative
stress. MDA concentration will be determined by using the
method described by Draper and Hadley based on TBA reactivity.
Normal Range of MDA is 3.60 ± 0.90 nanomole/ml . Controls
received standard medical therapy alone after PCI where as cases,
in addition, received 500 milligrams of Ranolazine twice a day for
6 months. All Echocardiographic parameters were reassessed
after 6months andmalonaldehyde concentrationswere repeated.
Minitab 16 version is used for statistical analysis.
Results: Male: Female ratio was 3.4:1 in cases and in controls. The
mean age of cases was 56.8 ± 9.6 yrs in cases and 55.1 ± 12 yrs in
controls. Basal clinical demographic features and risk factors are
comparable between cases and controls. After 6 months of Rano-
lazine therapy there was a statistically significant improvement in
EF{(46.1±10.5) to (48.32±9.63%)} and {(44.2±10.8)to (43.85±8.38%)}(
p¼0.008) by diameter and volume [(43.8±9.3) to (46.72±9.34ml)] and
[(41.8±9.52) to (42.55±9.1 ml)] p¼0.018) in cases and controls
respectively in comparison to baseline and there was improve-
ment in MAV [(9.5±2.1) to (9.79±1.84)] and [(8.8±1.8) to (8.65±1.8)]
(p¼0.001) in cases and controls respectively indicating the positive
remodeling effects of drug on LV parameters Plasma MDA levels
also showed improvement in cases than in controls. MDA at 6
months in cases was decreased from 3.6 nanomole/dl to 3.4±0.8
nanomole/dl where as in controls increased 3.8 to 3.9±0.7 nano-
mole/dl. Analysis of variance (ANOVA) was performed to check
whether there is any significant difference between the basal
values, 6 months control & with drug. It can be inferred from the
study that theeffect ofRanolazineon left ventricular remodeling in
obstructive coronary artery disease patients is highly significant
(p¼0.001 ) and has the potential to reduce the risk considerably.
Conclusions: Peak Mitral velocities can be used to follow the cases
in clinical practice to know the improvement in LV contractility
like standard EF. There is significant improvement in EF in cases
when compared to controls at 6 months, reconfirming the results
from the PMAV analysis. There is reduction in oxidative stress
levels in cases than controls at 6 months, may be possible
mechanism of action of ranolazine induced positive LV remodel-
ing.
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Background: Peripartum cardiomyopathy is a rare disorder
effecting women in their prime years of life. There appears to be
an initial high-risk period with 25% to 50% of women dying within
the first 3 months postpartum. Early risk stratification and prog-
nostication are, thus, crucial. However, only limited data are
available.
Objectives: We sought to determine the prognostic use of
inotropic contractile reserve on risk stratification and prognosti-
cation of women with peripartum cardiomyopathy.
Methods: In all, 10 women (mean age 20.7 years) with peripartum
cardiomyopathy and severe left ventricular (LV) dysfunction
(mean LV ejection fraction [LVEF] 27.3 + 6.5%) were studied. Of
these, 8 underwent dobutamine stress echocardiography at
baseline and a follow-up resting echocardiogram at a mean of 3.6
+ 0.9 months after initial presentation. Resting and peak inotropic
contractile reserve, and follow-up LVEF, were computed.
Results: Themean LVEF improved significantly frombaseline (27.3
+ 6.5%) to maximal inotropic contractile reserve (52.6 + 11.2%) (P _
.0004) and at follow-up (54.2 _ 14.3%) (P _ .006). Importantly, LVEF
at maximal inotropic contractile reserve and at follow-up (3.6
months) did not differ significantly. The mean LVEF at maximal
inotropic contractile reserve correlated well with the follow- up
(LVEF R _ 0.79). However, the baseline LVEF did not correlate with
follow-up LVEF.
Conclusions: In patients presenting with peripartum cardiomy-
opathy, inotropic contractile reserve during dobutamine stress
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